scholarly journals Sunitinib in metastatic renal cell carcinoma patients with brain metastases

Cancer ◽  
2010 ◽  
Vol 117 (3) ◽  
pp. 501-509 ◽  
Author(s):  
Martin E. Gore ◽  
Subramanian Hariharan ◽  
Camillo Porta ◽  
Sergio Bracarda ◽  
Robert Hawkins ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastases ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

scholarly journals Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions

2019 ◽  
Vol 26 (8) ◽  
pp. 849-850
Author(s):  
Hiroki Ishihara ◽  
Tsunenori Kondo ◽  
Toshio Takagi ◽  
Kazuhiko Yoshida ◽  
Masayoshi Okumi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastases ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Case Series ◽  
Developing Brain

scholarly journals Differences Between Patients (Pts) with Metastatic Renal Cell Carcinoma (Mrcc) Who Develop Brain Metastases (Bm) Versus Those Who Do Not

2014 ◽  
Vol 25 ◽  
pp. iv286
Author(s):  
L. Derosa ◽  
G. Le Teuff ◽  
L. Albiges Sauvin ◽  
Y. Loriot ◽  
C. Massard ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Brain Metastases ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy

2018 ◽  
Vol 104 (6) ◽  
pp. 444-450 ◽  
Author(s):  
Ibrahim Yildiz ◽  
Ahmet Bilici ◽  
Nuri Karadurmuş ◽  
Leyla Ozer ◽  
Deniz Tural ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Brain Metastases ◽  
Cell Carcinoma ◽  
Median Time ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Initial Diagnosis ◽  
Histological Subtype ◽  
Systemic Metastasis

Background: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. Patients and methods: Fifty-eight patients from 16 oncology centers for whom complete clinical data were available were retrospectively reviewed. Results: The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70.7%), were male (n = 42; 72.4%) and had clear-cell (CC) RCC (n = 51; 87.9%). Patients were treated with first-line suni-tinib (n = 45; 77.6%) or pazopanib (n = 13; 22.4%). The median time from the initial RCC diagnosis to the diagnosis of BMs was 9 months. The median time from the first occurrence of metastasis to the development of BMs was 7 months. The median overall survival (OS) of mRCC patients with BMs was 13 months. Time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months; p = 0.001), histological subtype (non-CC; p<0.05) and number of BMs (>2; p<0.05) were significantly associated with OS in multivariate analysis. There were no cases of toxic death. One mRCC patient with BMs (1.7%) experienced treatment-related cerebral necrosis. All other toxicities included those commonly observed with VEGF-TKI therapy. Conclusions: The time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months), a non-CC histological subtype, and a greater number of BMs (>2) were independent risk factors for a poor prognosis.

The enrollment status of patients with brain metastases in metastatic renal cell carcinoma: A query of clinicaltrials.gov.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e16070-e16070
Author(s):  
Tri Cao Le ◽  
James Brugarolas
Keyword(s):  
United States ◽  
Renal Cell Carcinoma ◽  
Brain Metastases ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
The United States ◽  
Cns Metastases ◽  
Exclusion Criteria ◽  
Cns Metastasis

e16070 Background: Clinical trials routinely exclude patients with brain metastases in metastatic renal cell carcinoma (mRCC). However, the degree to which such patients are excluded has not been documented. Routine exclusion of such patients limits applicability of trial results and obfuscates potential benefit in this subpopulation. This study aims to systematically determine the status of central nervous system (CNS) disease exclusion, with or without leptomeningeal disease, in clinical trial enrollment in interventional studies of mRCC. Methods: ClinicalTrials.gov was systematically queried to characterize the CNS exclusion criteria among open, interventional trials in mRCC. Results: Of 121 open trials, 29 (24%) strictly excluded patients with CNS metastasis. 69 trials (57%) enrolled patients with CNS metastasis with contingencies (i.e. prior CNS-directed local therapy, and/or lack of neurologic symptoms). Two trials (2%) enrolled patients with CNS metastasis without exception. 21 trials (17%) did not specify enrollment criteria with respect to CNS disease. In multivariate analysis of the effect of trial phase, location, sponsor, treatment type, and histologic subtype on CNS exclusion criteria, only location had a statistically significant effect. Trials performed exclusively within the United States had higher odds of excluding patients with CNS metastases than global trials (OR = 8.889, 95% CI: 1.405-56.251, p = 0.023) or trials performed exclusively outside of the United States (OR = 2.778, 95% CI: 1.054-1.758, p = 0.053). Conclusions: Due to the high rate of exclusion of patients with brain metastases in mRCC, many trial results cannot be reliably generalized to this subpopulation. Consideration should be given to looking at the effect of new systemic therapies on patients with CNS metastases to clarify benefit or harm in this subpopulation.

Sign in / Sign up

Export Citation Format

Share Document